Recommendations on introducing cannabinoids and tapering opioids in chronic pain controlCanadian-based group develops consensus guidance and algorithm to safely introduce and titrate cannabinoids while tapering opioids in patients with chronic pain Sexual dysfunction may persist after discontinuing SSRI or SNRI antidepressantsHealth Canada safety review reports on risk of persistent, worsening or new sexual dysfunction after stopping SSRI or SNRI treatment. Usual doses of tramadol may cause visual and auditory hallucinations Health Canada safety review identifies new risk, particularly in people older than age 65. Combogesic, first acetaminophen–ibuprofen fixed-dose combox, now available Nonprescription product approved for short-term management of mild/moderate acute pain and for reduction of fever, in adults. Methadone as a pain treatment Managing people with opioid-use disorder in the emergency department Canadian Association of Emergency Physicians offers recommendations for emergency healthcare providers to help address Canada’s opioid crisis. U.S. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later U.S. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later NSAIDs may cause rare kidney problems in unborn babies and/or low levels of amniotic fluid. 5 Tips: Managing lower back pain Guidelines recommend pharmacists provide take-home naloxone to all opioid users Take-home naloxone kits are publicly funded in all Canadian provinces and territories and have been shown to effectively reduce opioid-related deaths. Emgality (galcanezumab) now indicated to reduce cluster headache frequency CGRP binding antibody is first drug approved by Health Canada to help prevent episodic cluster headaches First Previous 9 10 11 12 13 Next Last
